Brain Cancer Clinical Trials in Washington

Showing 21-40 of 85 trials

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical trial based on the genetic alterations identified in their tumor.

High Grade GliomaDiffuse Intrinsic Pontine GliomaAnaplastic Astrocytoma+6 more

Nationwide Children's Hospital350 participantsStarted Aug 2024

Aurora, Colorado, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +18 more locations

RECRUITINGEARLY Phase 142 miles

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

NCT04655404

This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with chemotherapy in your children; as well as the safety larotrectinib when given post-focal radiation therapy.

High Grade GliomaDiffuse Intrinsic Pontine Glioma

Nationwide Children's Hospital15 participantsStarted Apr 2021

Aurora, Colorado, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +18 more locations

Targeted Pediatric High-Grade Glioma Therapy

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Brain Cancer Trials in Other Cities

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

DAY101 In Gliomas and Other Tumors

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Cancer Stem Cell High-Throughput Drug Screening Study

A Pilot RCT of the PRISM Intervention for AYAs With Cancer

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Other Conditions in Washington